Novacyt (FR:ALNOV) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Novacyt S.A., a molecular diagnostics company, reported a promising H1 2024 with unaudited revenues of approximately £10.3 million, marking a significant increase from the previous year’s £3.3 million. The growth is partly attributed to Yourgene Health’s contributions and strong performance in reproductive health and NIPT technologies. Despite a challenging trading environment, the company is on track for cost reductions following the Yourgene acquisition and is focusing on an R&D pipeline expected to yield new products within the next three years.
For further insights into FR:ALNOV stock, check out TipRanks’ Stock Analysis page.
